RxDoctor Payments Data

Mohammad Massoomi, MD

Interventional Cardiology · Gainesville, FLNPI 1538393715

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (42.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 48.6% of the total. Reporting peaked in 2019 at $10,670 and has fallen 74.6% since, to $2,709 in 2025.

$17,647in general payments, 2019–2025

Across 77 payments — averaging $229.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$9K
  • Abiomed$3K
  • Abbott$3K
  • Edwards Lifesciences$495
  • Boston Scientific$493
  • Medtronic$470
  • plus $1K from 12 others
$145,454in research payments, 2019–2025

Across 55 payments — averaging $2644.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Roche Diagnostics Operations, Inc.$105K
  • Abbott$41K

What the payments were for

  • Consulting fees$7,50043%
  • Travel & lodging$3,98323%
  • Food & beverage$6,12135%
  • Education$430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,647 in reported general payments places this provider in the 70th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida →

Medicare billing

Part B allowed, 2024
$189,503
Medicare patients
2,569
Services billed
4,321

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban49$52,564
EntrestoSacubitril/Valsartan17$27,060
Repatha SureclickEvolocumab17$17,472
JardianceEmpagliflozin11$11,582
Metoprolol Succinate58$876
Atorvastatin Calcium62$773
Rosuvastatin Calcium15$218
Losartan Potassium27$194
Carvedilol30$194
Ezetimibe16$188
Lisinopril26$160
Isosorbide Mononitrate ErIsosorbide Mononitrate17$141
Amlodipine Besylate17$136
ClopidogrelClopidogrel Bisulfate13$132
Nitroglycerin12$123

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Gainesville

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →